Skip to main content
Figure 6 | BMC Cancer

Figure 6

From: Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype

Figure 6

Additive antitumor activity of dasatinib and Eto in MDA-MB-231 cells. The cells were treated with indicated concentrations of dasatinib and/or 0.1 μM Eto for three days. Eto additively inhibited the growth of MDA-MB-157 cells. Open circles represent values treated with dasatinib alone. Closed circles represent values treated with Eto plus dasatinib. The values are expressed as mean ± S.E. of at least two separate experiments.

Back to article page